PL3833760T3 - Terapia oparta na mikrorna celowana przeciwko nowotworom złośliwym lcp-1-dodatnim - Google Patents

Terapia oparta na mikrorna celowana przeciwko nowotworom złośliwym lcp-1-dodatnim

Info

Publication number
PL3833760T3
PL3833760T3 PL19746427.4T PL19746427T PL3833760T3 PL 3833760 T3 PL3833760 T3 PL 3833760T3 PL 19746427 T PL19746427 T PL 19746427T PL 3833760 T3 PL3833760 T3 PL 3833760T3
Authority
PL
Poland
Prior art keywords
microrna
lcp
based therapy
targeted against
positive cancers
Prior art date
Application number
PL19746427.4T
Other languages
English (en)
Inventor
Marianna PROKOPI
Original Assignee
Theramir Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramir Ltd filed Critical Theramir Ltd
Publication of PL3833760T3 publication Critical patent/PL3833760T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL19746427.4T 2018-08-08 2019-08-08 Terapia oparta na mikrorna celowana przeciwko nowotworom złośliwym lcp-1-dodatnim PL3833760T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18020374 2018-08-08
PCT/EP2019/071341 WO2020030750A1 (en) 2018-08-08 2019-08-08 Microrna-based therapy targeted against lcp-1 positive cancers

Publications (1)

Publication Number Publication Date
PL3833760T3 true PL3833760T3 (pl) 2024-10-21

Family

ID=63207480

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19746427.4T PL3833760T3 (pl) 2018-08-08 2019-08-08 Terapia oparta na mikrorna celowana przeciwko nowotworom złośliwym lcp-1-dodatnim

Country Status (16)

Country Link
US (2) US12133860B2 (pl)
EP (2) EP3833760B1 (pl)
JP (2) JP7545970B2 (pl)
KR (1) KR102763998B1 (pl)
CN (1) CN112567034A (pl)
AU (1) AU2019319623B2 (pl)
BR (1) BR112021002321B1 (pl)
CA (2) CA3299361A1 (pl)
EA (1) EA202190474A1 (pl)
ES (1) ES2989876T3 (pl)
IL (1) IL280622A (pl)
MX (1) MX2021001517A (pl)
MY (1) MY209907A (pl)
PL (1) PL3833760T3 (pl)
SG (1) SG11202101069SA (pl)
WO (1) WO2020030750A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
CN111643527B (zh) * 2020-07-22 2020-12-29 广东赛尔生物科技有限公司 转基因干细胞外泌体在制备药物或美白化妆品中的用途
CN112294960B (zh) * 2020-10-30 2022-02-08 浙江大学 微小分子RNA-30b-5p作为靶分子的用途
WO2022154601A1 (ko) * 2021-01-14 2022-07-21 연세대학교 산학협력단 신규 췌장암 바이오마커 및 이의 용도
CN114350800B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
CN117802235B (zh) * 2022-09-30 2025-08-19 上海思路迪生物医学科技有限公司 血液胞外囊泡miRNA在卵巢癌诊断中的应用
WO2025101658A1 (en) * 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of lumbar facet joint syndrome
TW202535437A (zh) * 2023-11-07 2025-09-16 美商迪瑞克特生物製劑有限責任公司 使用胞外囊泡組合物之長新冠(long covid)之治療
WO2025101663A1 (en) * 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of graft-versus-host disease
WO2025101659A1 (en) * 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of irradiated skin
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
CN120093775B (zh) * 2025-01-24 2026-02-13 广州医科大学附属第一医院(广州呼吸中心) miR-30a-5p在制备治疗气道狭窄的产品中的应用
CN121622727A (zh) * 2026-02-05 2026-03-10 江西农业大学 MiR-30e-5p在肉鸡肺动脉高压诊疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010294197C9 (en) 2009-09-10 2018-09-13 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
WO2013048734A1 (en) 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes
PL2922554T3 (pl) * 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US20160002597A1 (en) * 2013-02-12 2016-01-07 Reneuron Limited Method of producing microparticles
WO2016166600A1 (en) * 2015-04-15 2016-10-20 Trojantec Technologies Ltd Delivery of microrna using mesenchymal stem cell microparticles
WO2017005773A1 (en) 2015-07-07 2017-01-12 Universite de Bordeaux Use of catenin- beta 1-targeting micrornas for treating liver cancer
KR101737706B1 (ko) 2015-12-15 2017-05-18 한국원자력의학원 miR-5582-5p를 포함하는 항암제
US20180127786A1 (en) * 2016-09-23 2018-05-10 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing

Also Published As

Publication number Publication date
JP2024095750A (ja) 2024-07-10
SG11202101069SA (en) 2021-03-30
JP7545970B2 (ja) 2024-09-05
ES2989876T3 (es) 2024-11-28
CA3299361A1 (en) 2026-03-02
MX2021001517A (es) 2021-04-19
KR102763998B1 (ko) 2025-02-07
NZ772466A (en) 2025-02-28
CN112567034A (zh) 2021-03-26
BR112021002321A2 (pt) 2021-05-11
EP4424380A3 (en) 2024-11-20
EA202190474A1 (ru) 2021-04-15
EP3833760C0 (en) 2024-07-17
MY209907A (en) 2025-08-11
CA3108172A1 (en) 2020-02-13
EP3833760A1 (en) 2021-06-16
JP7790811B2 (ja) 2025-12-23
KR20210044247A (ko) 2021-04-22
BR112021002321B1 (pt) 2023-11-28
EP4424380A2 (en) 2024-09-04
US20250057869A1 (en) 2025-02-20
JP2021533822A (ja) 2021-12-09
AU2019319623A1 (en) 2021-02-25
US12133860B2 (en) 2024-11-05
AU2019319623B2 (en) 2026-01-29
EP3833760B1 (en) 2024-07-17
WO2020030750A1 (en) 2020-02-13
US20210369760A1 (en) 2021-12-02
IL280622A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
IL280622A (en) A microRNA-based therapy targeting lcp-1-positive cancer
IL271946A (en) Combination for cancer treatment
IL259017A (en) Cancer cure is intended
GB201804255D0 (en) Macrophage-based therapy
IL277336A (en) combined treatment
ZA202005847B (en) Cancer therapy
GB201707153D0 (en) Therapy
GB201708663D0 (en) Therapy
GB201719646D0 (en) Therapy
IL310084B2 (en) Integrated and focused treatment
ZA201904736B (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy
GB201819853D0 (en) Therapy
IL280729A (en) Combined treatment
IL279908A (en) Combined treatment
SG11202101518QA (en) Combination therapy
GB201704909D0 (en) Cancer therapy
GB201817385D0 (en) Therapy
GB201711855D0 (en) Cancer therapy
GB201820895D0 (en) Therapy
GB201806463D0 (en) Cancer therapy
GB201814038D0 (en) Ilven therapy
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy
GB201815579D0 (en) Combination therapy
GB201814207D0 (en) Combination Therapy